Long-Term Tofersen Use May Slow ALS Progression, 3-Year Data Suggest

(MedPage Today) — Early initiation of tofersen (Qalsody) was associated with numerically slower decline in people with amyotrophic lateral sclerosis (ALS) SOD1 compared with delayed treatment, according to data from the VALOR trial and its open-label study…